Bacteria
Escherichia coli (other strains)
Strain/Type
ATCC 11775 = CCUG 24 = CCUG 29300 = CIP 54.8 = DSM 30083 = JCM 1649 = LMG 2092 = NBRC 102203 = NCCB 54008 = NCTC 9001.
Host tropism
Humans, various animal species.
Route of Transmission
Transmission takes place percutaneously (through the skin).
Transmission takes place orally (by ingestion).
The main transmission route of enteropathogenic E. coli is by the faecal-oral route, either from human to human or via foods or bodies of water contaminated by faecal matter.
Extraintestinal E. coli may also penetrate through injured skin.
Zoonosis (transmission between animals and humans): Yes
Animal to human transmission is possible in principle. However, humans are the primary (or sole) known reservoir for typical EPEC and EIEC. The extent to which animal to human transmission plays a role is unclear.
The main transmission route of enteropathogenic E. coli is by the faecal-oral route, either from human to human or via foods or bodies of water contaminated by faecal matter.
Extraintestinal E. coli may also penetrate through injured skin.
Characteristics e.g. sensitizing or toxic effects, resistance to antibiotics
Characteristics of pathogenicity:
Human-pathogenic (causes diseases in humans).
Animal-pathogenic (causes diseases in animals).
Pathogenic to humans and various vertebrates such as cattle, pigs, domestic cats, and poultry. Young children and elderly individuals are especially affected. Contact with the pathogen does not result in clinically manifest illness in every case. Humans and animals may excrete pathogenic E. coli without any visible signs of disease. Taking proton pump inhibitors (gastric acid inhibitors) favours the development of clinically manifest E. coli infections in humans (this applies to all diarrhoeal pathogens).
Toxigenicity/Toxin formation:
Unlike enterohaemorrhagic E. coli (EHEC, VTEC, STEC), other E. coli do not produce cytotoxins (Shiga
toxins).
Nonetheless, various other pathovars (especially including ETEC, EaggEC) form heat-resistant enterotoxins (EAST) whose role in diarrhoeal diseases is not yet fully explained.
Resistences:
Multiple resistances to antibiotics are observed frequently. However, since treatment with antibiotics plays virtually no role in the treatment of E. coli-related diarrhoeal disease, the development of antibiotic resistances is secondary.
This is unlike infections with extraintestinal E. coli, especially in meningitis, sepsis or urinary tract infection, which are generally treated with antibiotics. Here, the development of resistances, also to reserve antibiotics such as colistin, is alarming.
Note TA:
Types of which strains are known which have been handled safely over many years in technical applications. These proven strains can therefore be assigned to risk group 1 according to the classification criteria. The "TA" tag lays no claim of completeness, however. Strains with the features of "TA" may therefore also arise in species not bearing this tag.
Note ht:
Pathogenic for humans and vertebrates, but normally no transmission between the two host groups.
Approved as biological safety measure if taken as recipient organism for genetic engineering?
Genetically modified (GenTSV)
Risk group (BioStoffV)
2
Risk assessment
Risk accessment based on TRBA (Technical Rule for Biological Agents) 466 "Classification of prokaryotes (bacteria and archaea) into risk groups": https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Regelwerk/TRBA/TRBA-466.html
Occupational health care (according to ArbMedVV)
Optional health care
Storage location of aliquots in the Biolab (just click Bearbeiten in the right corner of the header to add or change information in the table and use the menue in the left header to e.g. add a row)
source | freezing date | amount of bacteria per vial | stock was produced on | no. of aliquots | belongs to (full name) | rack/box in N2 tank or -80°C freezer and location (room, address) | comments |
---|---|---|---|---|---|---|---|